Royalty Report: Drugs, Antibody, cardiac – Collection: 230756


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Antibody
  • cardiac
  • Disease
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 230756

License Grant
For the Patent License For Commercialization of Products, Licensor grants a worldwide, exclusive license or sublicense, in the Field, under Licensor Patents and Licensors interest in Joint Patents, with the right to grant sublicenses, to make, have made, use, import, and offer for sale and sell Products.

For the Know-how License, Licensor grants to
– an exclusive worldwide license to use Licensor Know-how within the Field, wherein such Know-how is solely related to the Collaboration Inhibitor including but not limited to the non-clinical development, process development, manufacturing, clinical development, and marketing of a Collaboration Inhibitor, in pursuance of the Research & Development Plan, during the Collaboration Term, and during the remaining Term of this Agreement.
– a non-exclusive worldwide license to use Licensor Know-how within the Field, wherein such Know-how is related to a Collaboration inhibitor including but not limited to the non-clinical development, and marketing of a Collaboration Inhibitor, in-pursuance of the Research & Development Plan, during the Collaboration Term, and during the remaining Term of this Agreement.

License Property
The patents include but are not limited to Methods and Compositions for the Treatment of  Inflammatory Diseases; Methods and Compositions for the Treatment of glomerulonephritis and other Inflammatory Diseases; Use Of C5-Specific / Antibodies For Reducing Immune And Hemostatic Dysfunctions During Extracorporeal Circulation; Recombinant DNA Products And Methods; and, Single Polypeptide Chain Molecules.

The Collaboration Inhibitor means the humanized anti-C5 monoclonal antibody coded h5G 1.1-ScFv and analogs, derivatives and formulations thereof owned or otherwise Controlled by Licensor.

Field of Use
The Field means the research, development, commercialization and use of Collaboration Inhibitor.  The field of competition is considered any pharmaceutical compound or product that specifically inhibits the production of C5a or specifically inhibits interaction with its receptor and in either case which is developed for use in acute cardiovascular conditions and/or applications and which is not a Product.

IPSCIO Record ID: 260433

License Grant
The purpose of this agreement is to exclusively collaborate on the development of one or more products binding to and inhibiting the activity of GM-CSF.

The German Licensor grants to the German Licensee an exclusive license, with the right to grant sublicenses, to the Licensed Technology, other than the Sublicensed Patents and the Sublicensed Know-How, to conduct research and development, make, have made, use, Commercialize, and import the Products in the Field in the Territory.

Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under the rights and licenses granted to Licensor in the Upstream Agreements with respect to the Sublicensed Technology, to research, develop, Commercialize, make, have made, use, offer for sale, sell, and import the Products in the Field in the Territory.

This agreement includes a non-exclusive grant beck from Licensee to Licensor.

License Property
Licensor is developing the MT203 Product, an anti-GM-CSF IgG1 antibody.

GM-CSF means the whole or part and natural variants of the granulocytemacrophage colony stimulating factor (GM-CSF) identified by the SWlSS-PROT entry name CSF2 _ HUMAN and accession number P04141 with the amino acid sequence as defined.

MT203 Product means any pharmaceutical product comprising the IgG1 antibody with the variable domain amino sequence.

The patents are for Antibody neutralizers of human granulocyte macrophage colony stimulating factor; and,  Method of identifying binding site domains that retain the capacity of binding to an epitope.

Field of Use
The Field means the treatment of human diseases and conditions.   The MT203 human antibody neutralizing the activity of granulocyte macrophage colony – stimulating factor (GM-CSF),  has potential applications in the treatment of inflammatory and autoimmune diseases.

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.